Makris Angela P, Rush Craig R, Frederich Robert C, Taylor Alisia C, Kelly Thomas H
Center for Obesity Research and Education, Temple University, Philadelphia, PA 19140, USA.
Exp Clin Psychopharmacol. 2007 Apr;15(2):123-33. doi: 10.1037/1064-1297.15.2.123.
Modafinil is indicated for the management of excessive daytime sleepiness; however, recent studies have examined a broad range of potential uses. Given that clinical uses of modafinil may be expanding, this study compared modafinil and d-amphetamine effects on subjective and performance measures. Across 11 sessions, 11 healthy adults were tested after oral doses of placebo (5 sessions), modafinil (1.75 mg/kg, 3.50 mg/kg, or 7.00 mg/kg), and d-amphetamine (0.035 mg/kg, 0.070 mg/kg, 0.140 mg/kg) under double-blind, randomized conditions. Assessments of cognitive performance and subjective effects were completed before drug administration, 30 min after drug administration, and at hourly intervals after drug administration for 5 hr. Modafinil increased ratings on the Amphetamine and Morphine Benzedrine Group scales of the Addiction Research Center Inventory (ARCI) and increased ratings on the Vigor and Total Positive scales of the Profile of Mood States. d-Amphetamine increased visual analog ratings of feeling stimulated and liking the drug and increased ratings on the Morphine Benzedrine Group scale of the ARCI. Both medications significantly reduced visual analog scale ratings of feeling sleepy, and modafinil decreased ratings on the ARCI Pentobarbital-Chlorpromazine-Alcohol Group scale. Both medications sustained performance that deteriorated across time on the Sternberg Number Recognition Test. Modafinil also enhanced performance rate on the Digit-Symbol Substitution Task above baseline levels and increased response rate on the Repeated Acquisition of Response Sequences Task. These results suggest that modafinil engenders alerting effects and increases performance in healthy non-sleep-deprived individuals comparable with that of d-amphetamine.
莫达非尼适用于治疗日间过度嗜睡;然而,最近的研究探讨了其广泛的潜在用途。鉴于莫达非尼的临床用途可能正在扩大,本研究比较了莫达非尼和右旋苯丙胺对主观和行为指标的影响。在11个实验环节中,11名健康成年人在双盲、随机条件下口服安慰剂(5个环节)、莫达非尼(1.75毫克/千克、3.50毫克/千克或7.00毫克/千克)以及右旋苯丙胺(0.035毫克/千克、0.070毫克/千克、0.140毫克/千克)后接受测试。在给药前、给药后30分钟以及给药后每小时进行一次,持续5小时,完成对认知行为和主观影响的评估。莫达非尼提高了成瘾研究中心量表(ARCI)中苯丙胺和吗啡-安非他明组量表的评分,以及情绪状态剖面图中活力和总积极量表的评分。右旋苯丙胺提高了感觉兴奋和喜欢药物的视觉模拟评分,以及ARCI中吗啡-安非他明组量表的评分。两种药物均显著降低了感觉困倦的视觉模拟量表评分,莫达非尼降低了ARCI戊巴比妥-氯丙嗪-酒精组量表的评分。两种药物都维持了在斯特恩伯格数字识别测试中随时间恶化的行为表现。莫达非尼还提高了数字符号替换任务中的行为表现率,使其高于基线水平,并提高了重复获取反应序列任务中的反应率。这些结果表明,莫达非尼在健康、未睡眠剥夺的个体中产生警觉作用并提高行为表现,与右旋苯丙胺相当。